Literature DB >> 17067824

Corpus callosotomy in refractory idiopathic generalized epilepsy.

Sigmund Jenssen1, Michael R Sperling, Joseph I Tracy, Maromi Nei, Liporace Joyce, Glosser David, Michael O'Connor.   

Abstract

RATIONALE: A small percentage of patients with idiopathic generalized epilepsy (IGE) do not respond to medical therapy. Generalized tonic-clonic (GTC) seizures are especially debilitating and can be associated with severe injuries. The benefit, safety and effect of corpus callosotomy (CC) in patients with IGE have not been studied.
METHODS: We reviewed patients with presumed IGE who underwent CC between 1991 and 2000. Criteria for selection included history, examination, brain imagining, interictal and ictal EEG. All patients had refractory and debilitating tonic-clonic seizures (GTCS) and had failed four or more antiepileptic drugs. Seizure frequency was calculated per month over the last year and pre-operative baseline was compared to last follow-up using paired t-tests. IQ, executive function, language and verbal, non-verbal memory and quality of life (QOL) was compared before and after surgery. Serial EEGs after surgery were reviewed.
RESULTS: There were nine patients (seven men), mean age 37.9 (range: 22-49), mean IQ 87.3 (range: 75-107). All had anterior CC. Mean follow-up time was 5.4 years (range: 0.6-10.3 years). One patient died from sudden death in epilepsy 9 months after surgery. There was a significant reduction of GTC seizures from 6.3 to 1.1 (p<0.005). Four patients had more than 80% and eight more than 50% reduction. Of five patients with absence seizures, two became seizure free and one had more than 80% reduction and two worsened slightly, and of three with myoclonic seizures one had more than 90% reduction. One patient had completion of the CC with improvement of myoclonus and absence seizures, but not of GTC seizures and suffered a disconnection syndrome. Another had right frontal focal resection without improvement after new seizures of focal onset. Cognitive testing showed a good outcome (improved or no change) in all cognitive domains. Post-surgical EEG showed new focal slowing and sharp waves. There was no change in QOL.
CONCLUSION: CC can be effective in reducing GTC, absence and myoclonic seizures in patients with refractory IGE. These findings suggest that interhemispheric communication of the cerebral cortices plays an important role in the generation of seizures in IGE. Anterior CC appears safe while complete callosotomy has a risk of disconnection syndrome.

Entities:  

Mesh:

Year:  2006        PMID: 17067824     DOI: 10.1016/j.seizure.2006.09.003

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  5 in total

1.  When should corpus callosotomy be offered as palliative therapy?

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2010-01       Impact factor: 7.500

Review 2.  Rates and predictors of seizure outcome after corpus callosotomy for drug-resistant epilepsy: a meta-analysis.

Authors:  Alvin Y Chan; John D Rolston; Brian Lee; Sumeet Vadera; Dario J Englot
Journal:  J Neurosurg       Date:  2018-05-01       Impact factor: 5.115

3.  Structure, integrity, and function of the hypoplastic corpus callosum in spina bifida myelomeningocele.

Authors:  Jennifer T Crawley; Khader Hasan; H Julia Hannay; Maureen Dennis; Catherine Jockell; Jack M Fletcher
Journal:  Brain Connect       Date:  2014-08-15

4.  Asymmetric epileptic spasms after corpus callosotomy in children with West syndrome may be a good indicator for unilateral epileptic focus and subsequent resective surgery.

Authors:  Daiki Uchida; Tomonori Ono; Ryoko Honda; Yoshiaki Watanabe; Keisuke Toda; Shiro Baba; Takayuki Matsuo; Hiroshi Baba
Journal:  Epilepsia Open       Date:  2022-08-01

5.  Refractory juvenile myoclonic epilepsy: a meta-analysis of prevalence and risk factors.

Authors:  R Stevelink; B P C Koeleman; J W Sander; F E Jansen; K P J Braun
Journal:  Eur J Neurol       Date:  2018-10-07       Impact factor: 6.089

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.